{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:00:04Z","timestamp":1790683204306,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016293","name":"Elsie and Marvin Dekelboum Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 AG16574"],"award-info":[{"award-number":["P50 AG16574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG11378"],"award-info":[{"award-number":["R01 AG11378"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG41851"],"award-info":[{"award-number":["R01 AG41851"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG06786"],"award-info":[{"award-number":["U01 AG06786"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017312","name":"Lewy Body Dementia Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.neurobiolaging.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T23:26:41Z","timestamp":1466983601000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum"],"prefix":"10.1016","volume":"46","author":[{"given":"David S.","family":"Knopman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-8642","authenticated-orcid":false,"given":"Emily S.","family":"Lundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Weigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthi","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejal","family":"Kantarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Gunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Senjem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Machulda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosebud O.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley F.","family":"Boeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer's Demen. J. Alzheimer's Assoc."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.neurobiolaging.2015.08.007","article-title":"Mapping 3-year changes in gray matter and metabolism in Abeta-positive nondemented subjects","volume":"36","author":"Araque Caballero","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.mri.2009.01.006","article-title":"Computational anatomy with the SPM software","volume":"27","author":"Ashburner","year":"2009","journal-title":"Magn. Reson. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib6","doi-asserted-by":"crossref","first-page":"338ra366","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1212\/WNL.0000000000001209","article-title":"Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression","volume":"84","author":"Caroli","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","article-title":"The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease","volume":"52","author":"Delacourte","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib9","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1212\/WNL.0b013e3182166e96","article-title":"Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults","volume":"76","author":"Dickerson","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaneurol.2013.1062","article-title":"Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease","volume":"70","author":"Dore","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0197-4580(97)80306-5","article-title":"Modeling the relation between neurofibrillary tangles and intellectual status","volume":"18","author":"Duyckaerts","year":"1997","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib12","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/cercor\/bhr271","article-title":"CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects","volume":"22","author":"Ewers","year":"2012","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib13","series-title":"Data Analysis Using Regression and Multilevel\/Hierarchical Models","author":"Gelman","year":"2007"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease","volume":"41","author":"Gomez-Isla","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","article-title":"11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment","volume":"131","author":"Jack","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib18","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1212\/WNL.0000000000000386","article-title":"Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration","volume":"82","author":"Jack","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","article-title":"Brain beta-amyloid load approaches a plateau","volume":"80","author":"Jack","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamaneurol.2014.4821","article-title":"Age, sex, and APOE e4 effects on memory, brain structure, and beta-amyloid across the adult life span","volume":"72","author":"Jack","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1474-4422(14)70194-2","article-title":"Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study","volume":"13","author":"Jack","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib22","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1212\/WNL.52.7.1397","article-title":"Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment","volume":"52","author":"Jack","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib23","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1093\/brain\/awv283","article-title":"Different definitions of neurodegeneration produce similar frequencies of amyloid and neurodegeneration biomarker groups by age among cognitively non-impaired individuals","volume":"138","author":"Jack","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau PET imaging in aging and early Alzheimer's disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10654-011-9563-8","article-title":"The (mis)use of overlap of confidence intervals to assess effect modification","volume":"26","author":"Knol","year":"2011","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib27","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/jamaneurol.2015.2323","article-title":"Role of beta-amyloidosis and neurodegeneration in subsequent imaging changes in mild cognitive impairment","volume":"72","author":"Knopman","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib28","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","article-title":"Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease","volume":"78","author":"Knopman","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaneurol.2013.182","article-title":"Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly with \u03b2-amyloidosis","volume":"70","author":"Knopman","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib30","doi-asserted-by":"crossref","first-page":"16265","DOI":"10.1523\/JNEUROSCI.2170-12.2012","article-title":"Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia","volume":"32","author":"La Joie","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.neuroimage.2004.10.016","article-title":"No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects","volume":"24","author":"Lemaitre","year":"2005","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's Demen. J. Alzheimer's Assoc."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jamaneurol.2014.2031","article-title":"Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals","volume":"71","author":"Mormino","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","article-title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging","volume":"67","author":"Morris","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib36","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/brain\/awv050","article-title":"Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum","volume":"138","author":"Murray","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.neurobiolaging.2014.07.036","article-title":"Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment","volume":"36","author":"Nosheny","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib38","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/cercor\/bht017","article-title":"Association of gray matter atrophy with age, beta-amyloid, and cognition in aging","volume":"24","author":"Oh","year":"2014","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"Petersen","year":"2004","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23931","article-title":"Mild cognitive impairment due to Alzheimer\u2019s disease: criteria in the community","volume":"74","author":"Petersen","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1212\/WNL.0b013e3181f11d85","article-title":"Prevalence of mild cognitive impairment is higher in men than in women. The Mayo Clinic Study of Aging","volume":"75","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40478-015-0199-x","article-title":"Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease","volume":"3","author":"Pooler","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib43","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0b013e3182872830","article-title":"Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease","volume":"80","author":"Prestia","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000115751","article-title":"The Mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics","volume":"30","author":"Roberts","year":"2008","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/WNL.0b013e3182452862","article-title":"The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging","volume":"78","author":"Roberts","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1212\/WNL.0000000000000055","article-title":"Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal","volume":"82","author":"Roberts","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib47","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","article-title":"Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later","volume":"80","author":"Roe","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib48","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/archneurol.2011.167","article-title":"The dynamics of cortical and hippocampal atrophy in Alzheimer disease","volume":"68","author":"Sabuncu","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib49","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","article-title":"Age, neuropathology, and dementia","volume":"360","author":"Savva","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib50","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain","volume":"89","author":"Scholl","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/awp007","article-title":"MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers","volume":"132","author":"Schuff","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib52","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/brain\/aww023","article-title":"Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages","volume":"139","author":"Schwarz","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jnen\/59.8.733","article-title":"Sequence of Abeta-protein deposition in the human medial temporal lobe","volume":"59","author":"Thal","year":"2000","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2051-5960-2-26","article-title":"Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition","volume":"2","author":"Toledo","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/nimg.2001.0978","article-title":"Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain","volume":"15","author":"Tzourio-Mazoyer","year":"2002","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib56","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1212\/WNL.0b013e3182a8418b","article-title":"Preclinical AD predicts decline in memory and executive functions in subjective complaints","volume":"81","author":"van Harten","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib57","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1212\/WNL.0b013e3182704056","article-title":"Injury markers predict time to dementia in subjects with MCI and amyloid pathology","volume":"79","author":"van Rossum","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuroimage.2015.03.026","article-title":"Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease","volume":"113","author":"Vemuri","year":"2015","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib59","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ana.21953","article-title":"Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease","volume":"67","author":"Vemuri","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib60","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib61","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/brain\/awv029","article-title":"Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage","volume":"138","author":"Vos","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib62","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib63","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/01.wnl.0000324924.91351.7d","article-title":"MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study","volume":"71","author":"Whitwell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.06.003_bib64","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jalz.2012.10.012","article-title":"The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly","volume":"9","author":"Wirth","year":"2013","journal-title":"Alzheimers Dement."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458016301026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458016301026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T22:37:17Z","timestamp":1718663837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458016301026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":64,"alternative-id":["S0197458016301026"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.06.003","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}